Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma
Phase 2
Not yet recruiting
- Conditions
- Lung AdenocarcinomaStage IV Non-small Cell Lung CancerPD-1 InhibitorVEGF
- Interventions
- First Posted Date
- 2023-01-09
- Last Posted Date
- 2023-01-09
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT05675033
Recombinant Human Adenovirus Type 5 Injection Combined With PD-1 Monoclonal Antibody and Nab-paclitaxel in the Treatment of Patients With Liver Metastases From Malignant Melanoma
Phase 2
Not yet recruiting
- Conditions
- Malignant MelanomaLiver Metastases
- Interventions
- Drug: Recombinant Human Adenovirus Type 5 Injection,Camrelizumab,Nab-paclitaxel
- First Posted Date
- 2022-12-23
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT05664139
Almonertinib Plus Metronomic Oral Vinorelbine
Not yet recruiting
- Conditions
- EGFRThird-generation TKINSCLC
- Interventions
- First Posted Date
- 2022-12-23
- Last Posted Date
- 2022-12-23
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT05663177
TIL Cells for the Treatment of the Advanced Solid Tumors Patients
Early Phase 1
Not yet recruiting
- Conditions
- Solid Tumor
- Interventions
- Biological: Tumor Infiltrating Lymphocytes
- First Posted Date
- 2022-12-14
- Last Posted Date
- 2022-12-14
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 42
- Registration Number
- NCT05649618
TCR-T Cells for the Treatment NY-ESO-1-positive Advanced Solid Tumors
Early Phase 1
Not yet recruiting
- Conditions
- Solid Tumors
- Interventions
- Biological: TCR-T cells
- First Posted Date
- 2022-12-13
- Last Posted Date
- 2022-12-13
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT05648994
The First-line Treatment of RCLM With RAS Mutation Was Local Short-course Radiotherapy (SCRT) + PD-1+ Standard Therapy
Phase 2
Not yet recruiting
- Conditions
- Rectal Cancer
- Interventions
- Drug: PD-1Radiation: SCRT
- First Posted Date
- 2022-12-07
- Last Posted Date
- 2022-12-07
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT05640726
Tislelizumab Combined With Chemotherapy or Radiotherapy in the Treatment of Advanced or Recurrent Metastatic Elderly Esophageal Cancer
Phase 2
Not yet recruiting
- Conditions
- Esophageal Cancer
- Interventions
- First Posted Date
- 2022-11-28
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 130
- Registration Number
- NCT05628610
Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.
Phase 2
Recruiting
- Conditions
- Esophageal NeoplasmsDigestive System NeoplasmsEsophageal Diseases
- Interventions
- First Posted Date
- 2022-11-21
- Last Posted Date
- 2023-10-19
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 75
- Registration Number
- NCT05624099
- Locations
- 🇨🇳
Fujian Cancer Hospital, Fuzhou, China
Fluzopari Combined With Apatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer
- First Posted Date
- 2022-10-28
- Last Posted Date
- 2022-10-28
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 35
- Registration Number
- NCT05597527
- Locations
- 🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China
Surufatinib Combined With Irinotecan as a Second-line Treatment for Small Cell Lung Cancer
Phase 2
Not yet recruiting
- Conditions
- AngiogenesisChemotherapy EffectSmall Cell Lung Cancer
- Interventions
- First Posted Date
- 2022-10-27
- Last Posted Date
- 2022-11-29
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT05595889
© Copyright 2025. All Rights Reserved by MedPath